AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus

Key Takeaways AMGN beat Q4 EPS and sales estimates as total revenues rose 9% on strong global demand across key brands.Amgen saw robust growth from Repatha, Evenity and Tezspire, offsetting pricing pressure and higher costs.AMGN is advancing MariTide with six phase III obesity studies, targeting monthly dosing via autoinjector.Amgen (AMGN) reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of $4.76 per share. Earnings were relatively flat year over yea ...